Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Open Access
- 13 January 2006
- journal article
- case report
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 65 (8), 1033-1037
- https://doi.org/10.1136/ard.2005.046193
Abstract
Background: Primary Sjögren’s syndrome (SS) is associated with an increased frequency of non-Hodgkin’s lymphomas (NHLs), mainly of low histological grade. However, aggressive diffuse large B cell lymphomas (DLBCL) characterised by poor treatment outcome can also be encountered in SS. It has recently been shown that rituxan has significant therapeutic activity in this type of lymphoma. Objective: To evaluate the efficacy of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) in combination with rituxan in SS patients with DLBCL, and to determine the outcome in such patients. Methods: In an open, single case trial, six SS patients with DLBCL were assigned to receive eight cycles of CHOP every three weeks plus rituxan given on day 1 of each cycle. In a retrospective study, conducted by the European Concerted Action for SS, nine cases were diagnosed as DLBCL, all of whom had been treated with CHOP alone. These patients were used as historical controls. Results: The difference in the overall survival between the two treatment groups was significant. The group treated with rituxan plus CHOP had a 100% two year overall survival rate, while the historical controls had only a 37% survival rate. Extraglandular manifestations serving as predictors for lymphoma development such as palpable purpura and peripheral neuropathy disappeared. The remission of these signs was accompanied by a decrease in both circulating monoclonal cryoglobulins and rheumatoid factor activity and an increase in C4 levels. Clinically relevant toxicity was not detected. Conclusions: The addition of rituxan to standard CHOP chemotherapy results in improved treatment outcome in SS patients with aggressive DLBCL, without increasing toxicity.Keywords
This publication has 19 references indexed in Scilit:
- Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomasRheumatology, 2004
- Rituximab for Treatment of Advanced Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue LymphomaOncology, 2003
- Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapyArthritis & Rheumatism, 2003
- Efficacy and safety of rituximab in type II mixed cryoglobulinemiaBlood, 2003
- Humoral immunity and long-lived plasma cellsCurrent Opinion in Immunology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2001
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European communityArthritis & Rheumatism, 1993
- Increased Risk of Lymphoma in Sicca SyndromeAnnals of Internal Medicine, 1978